Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because of it?), led by a 22% gain in Provention Bio, we managed to put up...
Tailwinds' Take: nice to see that everything remains on track for PRVB. We expect to see the filing completed by year-end with PDUFA date in the first half of 2021. Tough to see the stock not dramatically higher once...
Tailwinds' Take: this is a very high quality addition to the board and lends a ton of credence to their diabetes programs. OLDWICK, N.J., Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to...
What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us small cap investors, it was particularly painful. There seemed to be zero bids out there...
OLDWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a...
Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible? Well, as many savvy investors have repeated numerous times over the years, don't fight the...
Greetings from Stresa Italy, a gorgeous town on the edge of Lake Maggiore. With great food, excellent wines and friendly people, Italy is always a great place to relax. This is especially true during times of market weakness, as...
Tailwinds' Take: Provention continues to build a team around the massive opportunity of tepluzimab. Hoitt has an impressive resume. We view his addition very positively. OLDWICK, N.J., Jan. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage...
OLDWICK, N.J., Aug. 6, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2019 and provided a business update. "The data from the...
Tailwinds' Take: all systems go for tepluzimab. We expect the stock to continue performing well as the company gets closer to the anticipated approval and subsequent launch of their groundbreaking T1D treatment. OLDWICK, N.J., May 7, 2020 /PRNewswire/ -- Provention...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.